Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients ; volume:16 ; number:1 ; day:22 ; month:9 ; year:2016 ; pages:1-11 ; date:12.2016
BMC cancer ; 16, Heft 1 (22.9.2016), 1-11, 12.2016
- Urheber
-
Anantharaman, Archana
- Beteiligte Personen und Organisationen
-
Friedlander, Terence
Lu, David
Krupa, Rachel
Premasekharan, Gayatri
Hough, Jeffrey
Edwards, Matthew
Paz, Rosa
Lindquist, Karla
Graf, Ryon
Jendrisak, Adam
Louw, Jessica
Dugan, Lyndsey
Baird, Sarah
Wang, Yipeng
Dittamore, Ryan
Paris, Pamela L.
SpringerLink (Online service)
- DOI
-
10.1186/s12885-016-2758-3
- URN
-
urn:nbn:de:1111-2016102311728
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:03 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Anantharaman, Archana
- Friedlander, Terence
- Lu, David
- Krupa, Rachel
- Premasekharan, Gayatri
- Hough, Jeffrey
- Edwards, Matthew
- Paz, Rosa
- Lindquist, Karla
- Graf, Ryon
- Jendrisak, Adam
- Louw, Jessica
- Dugan, Lyndsey
- Baird, Sarah
- Wang, Yipeng
- Dittamore, Ryan
- Paris, Pamela L.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Programmed death-ligand 1 (PD-L1) expression in various tumor types
The effect of hypoxia on PD-L1 expression in bladder cancer
PD-L1 expressing circulating tumour cells in head and neck cancers
Programmed death-ligand 1 (PD-L1) expression in primary gastric adenocarcinoma and matched metastases
Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation
Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation
Circulating PD-L1 levels change during bevacizumab-based treatment in recurrent glioma
Levels of Circulating PD-L1 Are Decreased in Patients with Resectable Cholangiocarcinoma
Exploratory analyses of treatment subgroup interaction by PD-L1 status and according to PD-L1 expression in the JAVELIN Bladder 100 trial
Characterisation of tumour-immune phenotypes and PD-L1 positivity in squamous bladder cancer
Characterisation of tumour-immune phenotypes and PD-L1 positivity in squamous bladder cancer
Genomic correlates of programmed cell death ligand 1 (PD-L1) expression in Chinese lung adenocarcinoma patients
Programmed death-ligand 1 (PD-L1) expression in various tumor types
The effect of hypoxia on PD-L1 expression in bladder cancer
PD-L1 expressing circulating tumour cells in head and neck cancers
Programmed death-ligand 1 (PD-L1) expression in primary gastric adenocarcinoma and matched metastases
Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation
Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation
Circulating PD-L1 levels change during bevacizumab-based treatment in recurrent glioma
Levels of Circulating PD-L1 Are Decreased in Patients with Resectable Cholangiocarcinoma
Exploratory analyses of treatment subgroup interaction by PD-L1 status and according to PD-L1 expression in the JAVELIN Bladder 100 trial
Characterisation of tumour-immune phenotypes and PD-L1 positivity in squamous bladder cancer
Characterisation of tumour-immune phenotypes and PD-L1 positivity in squamous bladder cancer
Genomic correlates of programmed cell death ligand 1 (PD-L1) expression in Chinese lung adenocarcinoma patients
Programmed death-ligand 1 (PD-L1) expression in various tumor types
The effect of hypoxia on PD-L1 expression in bladder cancer
PD-L1 expressing circulating tumour cells in head and neck cancers
Programmed death-ligand 1 (PD-L1) expression in primary gastric adenocarcinoma and matched metastases
Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation
Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation
Circulating PD-L1 levels change during bevacizumab-based treatment in recurrent glioma
Levels of Circulating PD-L1 Are Decreased in Patients with Resectable Cholangiocarcinoma
Exploratory analyses of treatment subgroup interaction by PD-L1 status and according to PD-L1 expression in the JAVELIN Bladder 100 trial
Characterisation of tumour-immune phenotypes and PD-L1 positivity in squamous bladder cancer
Characterisation of tumour-immune phenotypes and PD-L1 positivity in squamous bladder cancer